Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

Yes, B-OM can fall into oncology, but, it can just as easily fall into the IBD camp.

That's why I'm delighted to see the Aspire deal. It gives them the freedom to take the right deal instead of simply the first one.

I'm still in agreement with groton68 that the entire brilacidin platform goes to one pharma. But, isn't it great to see the many directions the company can go in?!?!







In Reply to 'biodoc'
groton68,one BP partner for the entire Brilacidin platform certainly makes sense. Also consider that B-OM is (1) a unique formulation that is easily separated from the rest of the Brilacidin platform and (2) falls within Oncology. I'd suggest that an oncology focused pharma could do a clean deal for B-OM and K. Deals across multiple drug company divisions within a BP could take a lot longer than one or two products within a single large division.

IPIX will,imo, have a range of options moving forward and the resources to move the pipeline forward until the right deal is penned.